Clinical Activity Demonstrated for Polyvalent Mutant KRAS Cancer Vaccine

Time: 12:30 pm
day: Day Two Track C

Details:

  • Robust immune responses and clinical benefit observed in pancreatic cancer
  • Product and treatment scheduling strategies to enhance KRAS immune responses
  • Future development plans and IO combination options to maximize benefit

Speakers: